MedPath

ENGENEIC PTY LIMITED

🇦🇺Australia
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

7

Active:1
Completed:1

Trial Phases

2 Phases

Phase 1:6
Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials

Phase 1
6 (85.7%)
Not Applicable
1 (14.3%)

A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer

Not Applicable
Not yet recruiting
Conditions
Pancreatic Cancer, Metastatic
PDAC - Pancreatic Ductal Adenocarcinoma
Interventions
Drug: EDV-GC
Drug: Nab paclitaxel.
First Posted Date
2025-07-03
Last Posted Date
2025-07-03
Lead Sponsor
Engeneic Pty Limited
Target Recruit Count
144
Registration Number
NCT07049055
Locations
🇺🇸

Columbia University Irving Medical Center, New York, New York, United States

A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM

Phase 1
Completed
Conditions
Astrocytoma, Grade IV
Glioblastoma
Interventions
Drug: EGFR(V)-EDV-Dox
First Posted Date
2016-05-10
Last Posted Date
2025-06-03
Lead Sponsor
Engeneic Pty Limited
Target Recruit Count
9
Registration Number
NCT02766699
Locations
🇺🇸

John Hopkins Hospital, Baltimore, Maryland, United States

🇺🇸

Lenox Hill Hospital, Northwell Health, New York, New York, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.